Transcript-based circulating tumor and cancer stem cell detection in inflammatory breast cancer: a six-year prospective evaluation of assay yield and prognostic performance

Abstract Inflammatory breast cancer (IBC) is a rare and aggressive presentation for which no validated blood-based monitoring tool exists, and the tumor emboli that define its biology have motivated interest in circulating tumor cell (CTC) assays. We prospectively evaluated a transcript-based platform combining epithelial CTC markers (MUC1, HER2, GA733-2) and cancer stem cell (CSC)-associated markers (TWIST, AKT, PI3K, ALDH1) in patients with stage III breast cancer enrolled from 2013 to 2020, comparing 54 patients with IBC against 23 with non-IBC disease across 222 quality-controlled serial samples. Using the manufacturer-defined positivity thresholds, 14% of samples were CTC-positive and 29% CSC-positive. No marker distinguished IBC from non-IBC at baseline: GA733-2 was positive in 7 of 54 IBC versus 1 of 23 non-IBC patients (p = 0.42), and the composite positive categories did not differ (p = 0.71 for CTC, p = 0.11 for CSC). HER2 and TWIST transcripts were undetectable at threshold in all 77 patients. Among 44 IBC patients evaluable for event-free survival over a median 65 months of follow-up, neither baseline CTC positivity (log-rank p = 0.10) nor CSC positivity (p = 0.55) stratified outcome. Threshold sensitivity analysis showed that detectable signal clustered an order of magnitude below the positivity cutoffs, so that no threshold produced both an adequate positivity rate and outcome discrimination. Positivity at any draw during follow-up, and an additive classification combining both marker classes, likewise showed no association with outcome. Benchmarked against a tumor-informed ctDNA assay evaluated by our group in the same disease setting, the two platforms showed near-identical sample-level positivity (29% versus 27%) and technical QC performance, yet only ctDNA positivity tracked disease trajectory and preceded radiographic relapse. These findings indicate that transcript-based CTC and CSC detection, as implemented here, does not provide clinically actionable risk stratification in IBC, and they support prioritizing sequencing-based circulating tumor DNA and next-generation CTC platforms for minimal residual disease monitoring in this population.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-10789073/v1
Primary Topic
Cancer Genomics and Diagnostics
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Transcript-based circulating tumor and cancer stem cell detection in inflammatory breast cancer: a six-year prospective evaluation of assay yield and prognostic performance

Megumi Kai, Lily Xu, James Mwikya Reuben, Joshua Haney et al.
Research Square
Cancer Genomics and Diagnostics
preprint

Transcript-based circulating tumor and cancer stem cell detection in inflammatory breast cancer: a six-year prospective evaluation of assay yield and prognostic performance

Megumi Kai, Lily Xu, James Mwikya Reuben, Joshua Haney, Elyse Lopez, Diego F. Chamorro, Vicente Valero, Bora Lim, Ahmed Shatta, Hui Gao
preprint en

Abstract

Abstract Inflammatory breast cancer (IBC) is a rare and aggressive presentation for which no validated blood-based monitoring tool exists, and the tumor emboli that define its biology have motivated interest in circulating tumor cell (CTC) assays. We prospectively evaluated a transcript-based platform combining epithelial CTC markers (MUC1, HER2, GA733-2) and cancer stem cell (CSC)-associated markers (TWIST, AKT, PI3K, ALDH1) in patients with stage III breast cancer enrolled from 2013 to 2020, comparing 54 patients with IBC against 23 with non-IBC disease across 222 quality-controlled serial samples. Using the manufacturer-defined positivity thresholds, 14% of samples were CTC-positive and 29% CSC-positive. No marker distinguished IBC from non-IBC at baseline: GA733-2 was positive in 7 of 54 IBC versus 1 of 23 non-IBC patients (p = 0.42), and the composite positive categories did not differ (p = 0.71 for CTC, p = 0.11 for CSC). HER2 and TWIST transcripts were undetectable at threshold in all 77 patients. Among 44 IBC patients evaluable for event-free survival over a median 65 months of follow-up, neither baseline CTC positivity (log-rank p = 0.10) nor CSC positivity (p = 0.55) stratified outcome. Threshold sensitivity analysis showed that detectable signal clustered an order of magnitude below the positivity cutoffs, so that no threshold produced both an adequate positivity rate and outcome discrimination. Positivity at any draw during follow-up, and an additive classification combining both marker classes, likewise showed no association with outcome. Benchmarked against a tumor-informed ctDNA assay evaluated by our group in the same disease setting, the two platforms showed near-identical sample-level positivity (29% versus 27%) and technical QC performance, yet only ctDNA positivity tracked disease trajectory and preceded radiographic relapse. These findings indicate that transcript-based CTC and CSC detection, as implemented here, does not provide clinically actionable risk stratification in IBC, and they support prioritizing sequencing-based circulating tumor DNA and next-generation CTC platforms for minimal residual disease monitoring in this population.

Research Square
The University of Texas MD Anderson Cancer Center (US), Baylor College of Medicine (US), University of Pittsburgh Medical Center (US), The University of Texas Health Science Center at Houston (US)
National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute
Good health and well-being
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon